GenFleet-B (02595) has announced that since the third quarter of this year, multiple innovative combination therapies involving its oral pan-RAS inhibitor GFH276 have received clinical trial approvals from China's CDE or completed clinical trial filings with Australia's TGA.
These studies cover first-line and later-line treatment for multiple major cancer types harboring RAS mutations, with some trials already having enrolled patients across several dose levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments